These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2005-000664-51 A RANDOMIZED DOUBLE-BLIND PARALLELL GROUP CLINICAL STUDY OF XENETIX 300 VERSUS VISIPAQUE 270 IN MULTISLICE CT PEDIATRIC INDICATIONS 2009-04-24 bad-data
Reported results 2006-001298-57 Comparison of the diagnostic efficacy of Xenetix 350 and Iomeron 400, for visualisation of the aorta and abdominal vascular tree with 64-slices computed tomography 2008-02-28 due-trials
Reported results 2007-000229-23 EVALUACIÓN DE LA SEGURIDAD RENAL TRAS ARM POTENCIADA CON DOTAREM EN COMPARACIÓN CON LA RM SIN CONTRASTE ENTRE PACIENTES CON ALTO RIESGO DE PADECER NEFROPATIA PROVOCADA POR EL MEDIO DE CONTRASTE RENA... 2011-05-09 due-trials
Reported results 2009-010968-42 Efficacy evaluation of DOTAREM-enhanced MRA compared to GADOVIST-enhanced MRA in the diagnosis of clinical significant abdominal or lower limb arterial diseases 2012-01-07 due-trials
Reported results 2009-011002-42 Intra-individual efficacy evaluation of DOTAREM®-enhanced MRA compared to GADOVIST®–enhanced MRA in the diagnosis of clinically significant abdominal or limb arterial diseases 2010-07-12 due-trials
Reported results 2010-020319-34 Evaluación de la seguridad y la eficacia de Dotarem en resonancia magnética (RM) en pacientes con lesiones del sistema nervioso central (SNC) SAFETY AND EFFICACY EVALUATION OF DOTAREM® IN MAGNETIC RE... 2011-11-16 due-trials
Reported results 2010-021826-37 Xenetix 350 : Evaluación comparativa de la calidad de imagen en la angiografía de las arterias coronarias mediante escáner Xenetix 350 : comparative assessment of image quality for coronary CT angiog... 2012-09-17 due-trials
Reported results 2011-002609-31 Diagnostic contribution of XENETIX® CT PERFUSION in pre-therapeutical assessment of hepatocellular carcinoma. 2015-12-18 due-trials
Reported results 2013-003215-21 DOTAREM® Pharmacokinetics, Safety and Efficacy Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive) DOTAREM® Studie zur Pharmakokinetik, Sicherhei... 2015-10-19 due-trials
Reported results 2014-003576-23 P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) Studio di ricerca della dose di P03277 in risonanze magnetiche per immagini (Magnetic Resonance Imaging, M... 2018-01-23 due-trials
Reported results 2016-002930-62 Proof of Concept study concerning efficacy of P03277 MR Imaging in HCC diagnosis Phase IIa Clinical Study Étude de preuve de concept relative à l’efficacité du P03277 dans l’imagerie par résonance... 2019-04-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-001516-30 Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, P03277, in pediatric patients from 2 to 17 years of age undergoing central nervous system contrast-enhanced MRI. 2020-08-10 bad-data
Reported results 2018-003946-18 Efficacy and safety of gadopiclenol for body magnetic resonance imaging (MRI) 2020-12-09 due-trials
Reported results 2018-003988-54 Efficacy and Safety of gadoPIClenol for CenTral NervoUs System (CNS) Magnetic REsonance Imaging (MRI) 2020-09-11 due-trials
Completed, report not yet due Terminated 2021-003825-31 Gadopiclenol Pharmacokinetics, Safety and Efficacy in Pediatric Patients < 2 Years of Age Undergoing Contrast-enhanced MRI P/0145/2019 2024-09-30 not-yet-due
Ongoing 2022-002720-12 Performance of Elucirem® (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas not-yet-due